The number of cell engineering partnerships Ginkgo Bioworks has is way up, but the same can't be said about its stock price. It has been difficult to be a shareholder of Ginkgo Bioworks (DNA 0.70%) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry is an amazing accomplishment, but sales have stagnated. If this business only needs a little more time for the industries it serves to notice its capabilities, investors who buy now could be gre ...